Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Aug 22, 2007
NEW HAVEN, Conn., Aug 22, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of David P. Wright to its Board of Directors. Mr. Wright, who is President and ...
PDF
Aug 8, 2007
NEW HAVEN, Conn., Aug 8, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and six months ended June 30, 2007. For the six months ende...
PDF
Jul 27, 2007
NEW HAVEN, Conn., Jul 27, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals Inc. (Nasdaq:ACHN) expects to release its results for the second quarter ended June 30, 2007 after the market closes on Wednesday, August 8, 2007. The company will host a conference call to discuss the results at 4:30 PM ET on August 8. The call ...
PDF
Jun 11, 2007
NEW HAVEN, Conn., Jun 11, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Milind Deshpande, Ph.D. has been promoted to Executive Vice President of Research. Dr. Des...
PDF
May 17, 2007
NEW HAVEN, Conn., May 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer, has resigned to accept a senior clinical development position at GlaxoSmithKline. His resignation will become effective on M...
PDF
May 16, 2007
NEW HAVEN, Conn., May 16, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate overv...
PDF
May 15, 2007
NEW HAVEN, Conn., May 15, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the appointment of Robert L. Van Nostrand to its Board of Directors. Mr. Van Nostrand, who is S...
PDF
May 9, 2007
NEW HAVEN, Conn., May 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc., (Nasdaq: ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter ended March 31, 2007. For the first quarter of 2007...
PDF
Apr 16, 2007
NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced the presentation of data validating the clinical antiviral activity of one of Achillion's NS4A antagonists, ACH-806, for the treatment of hepatitis C virus (HCV) infection at the 42nd Annual Meeting of th...
PDF
Mar 27, 2007
NEW HAVEN, Conn., March 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Achillion Pharmaceuticals, Inc., (Nasdaq: ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and year ended December 31, 2006. For the full y...
PDF
FirstPrevious
...
25
NextLast